Current communication practices for biomarker testing in non-small cell lung cancer: Exploring patient and clinician perspectives

被引:2
|
作者
Pack, Allison [1 ,2 ,7 ]
Russell, Andrea [1 ,2 ]
Kircher, Sheetal [1 ,2 ]
Weldon, Christine [1 ,2 ,3 ,4 ]
Bailey, Stacy C. [1 ,2 ]
Lockwood, Karen [5 ]
Marquart, Tyler [5 ]
Afonso, Ana Sofia [6 ]
Payakachat, Nalin [5 ]
Wolf, Michael [1 ,2 ]
机构
[1] Northwestern Univ, Ctr Appl Hlth Res Aging, Feinberg Sch Med, Chicago, IL USA
[2] Northwestern Univ, Div Gen Internal Med, Feinberg Sch Med, Chicago, IL USA
[3] Northwestern Univ, Div Obstet & Gynecol, Feinberg Sch Med, Chicago, IL USA
[4] Ctr Business Models Healthcare, Glencoe, IL USA
[5] Eli Lilly & Co, Indianapolis, IN USA
[6] Eli Lilly BV, Utrecht, Netherlands
[7] Northwestern Univ, Div Gen Internal Med, Feinberg Sch Med, 750 N Lake Shore Dr, 10th Floor, Chicago, IL 60611 USA
基金
美国国家卫生研究院;
关键词
Non -small cell lung cancer; Patient education; Biomarker testing; LITERACY;
D O I
10.1016/j.pec.2023.107839
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives: We qualitatively explored patient and clinician experiences with biomarker testing in one academic health system to identify current communication practices and unmet testing information needs. Methods: We conducted 1:1 in-depth interviews with 15 clinicians (i.e., nurses, oncologists, pathologists) and 12 patients diagnosed with non-small cell lung cancer between January and May 2022. Participants described experiences with biomarker testing as well as associated communication practices and needs. Interviews were audio-recorded and transcribed. Analysis was informed by the Framework Method. Results: Patients described challenges retaining information early in their patient journey. While patients were generally aware of biomarkers and their effect on treatment options, they expressed limited knowledge of expected time delays between testing and receiving results. Additionally, many did not know their testing results. Clinicians and patients both noted no standard education material on biomarker testing is currently available. They suggested such materials could support patient knowledge and decision-making. Conclusions: Communication between patients and clinicians about biomarker testing is largely delivered through verbal counseling at a time when patients may be cognitively compromised. All participants supported the idea of delivering standard, tangible education materials on biomarker testing to patients. Practice implications: Education materials may enhance counseling efforts and patient knowledge.
引用
收藏
页数:6
相关论文
共 50 条
  • [11] Biomarker Testing in Non-Small Cell Lung Carcinoma: Performance and Patient Outcomes
    Fadel, Saleh
    Chirip, Venus
    Wheatley-Price, Paul
    Reaume, Neil
    Lo, Bryan
    Chang, Nina
    Sekhon, Harmanjatinder
    Gomes, Marcio
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1103 - 1104
  • [12] Biomarker Testing in Non-Small Cell Lung Carcinoma: Performance and Patient Outcomes
    Fadel, Saleh
    Chirip, Venus
    Wheatley-Price, Paul
    Reaume, Neil
    Lo, Bryan
    Chang, Nina
    Sekhon, Harmanjatinder
    Gomes, Marcio
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 1103 - 1104
  • [13] Sotorasib for non-small cell lung cancer - current options and perspectives
    Knetki-Wroblewska, Magdalena
    Wasag, Bartosz
    ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (03): : 215 - 221
  • [14] Patient and Clinician Preferences for Genetic and Genomic Testing in Non-Small Cell Lung Cancer: A Discrete Choice Experiment
    Fifer, Simon
    Ordman, Robyn
    Briggs, Lisa
    Cowley, Andrea
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (06):
  • [15] Biomarker testing in non-small cell lung cancer: to move forward with quality
    Rolf Stahel
    Clinical and Translational Oncology, 2012, 14 : 321 - 322
  • [16] The evolving landscape of biomarker testing for non-small cell lung cancer in Europe
    Kerr, Keith M.
    Bibeau, Frederic
    Thunnissen, Erik
    Botling, Johan
    Ryska, Ales
    Wolf, Jurgen
    Ohrling, Katarina
    Burdon, Peter
    Malapelle, Umberto
    Buttner, Reinhard
    LUNG CANCER, 2021, 154 : 161 - 175
  • [17] Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer
    Ganti, Apar
    Hirsch, Fred R.
    Wynes, Murry
    Ravelo, Arliene
    Ramalingam, Suresh
    Ionescu-Ittu, Raluca
    Pivneva, Irina
    Borghaei, Hossein
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S964 - S965
  • [18] Biomarker testing in non-small cell lung cancer: to move forward with quality
    Stahel, Rolf
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (05): : 321 - 322
  • [19] What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer
    Riely, Gregory L.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (5.5): : 686 - 688
  • [20] The rapidly evolving landscape of biomarker testing in non-small cell lung cancer
    VanderLaan, Paul A.
    Rangachari, Deepa
    Costa, Daniel B.
    CANCER CYTOPATHOLOGY, 2021, 129 (03) : 179 - 181